Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

The Clinical Utility of Molecular Imaging Using Nuclear Medicine Tools in the Management of All Stages of Adult Gliomas

Version 1 : Received: 17 June 2024 / Approved: 17 June 2024 / Online: 17 June 2024 (13:01:02 CEST)

How to cite: Boshomane, T. M.; Kgatle, M. M.; Joseph, F.; Padayachy, L.; Bida, M.; Ebenhan, T.; Vorster, M.; Sathekge, M. M. The Clinical Utility of Molecular Imaging Using Nuclear Medicine Tools in the Management of All Stages of Adult Gliomas. Preprints 2024, 2024061159. https://doi.org/10.20944/preprints202406.1159.v1 Boshomane, T. M.; Kgatle, M. M.; Joseph, F.; Padayachy, L.; Bida, M.; Ebenhan, T.; Vorster, M.; Sathekge, M. M. The Clinical Utility of Molecular Imaging Using Nuclear Medicine Tools in the Management of All Stages of Adult Gliomas. Preprints 2024, 2024061159. https://doi.org/10.20944/preprints202406.1159.v1

Abstract

Gliomas are common primary central nervous system (CNS) tumours which are often very difficult to diagnose, stage and manage because of their heterogeneity and molecular aberrations. The notable hallmark of gliomas is integrated genome mutations and methylome that correlates with distinctive patterns of transcription that potentiates glioma heterogeneity, angiogenesis and ultimately poor prognosis. The World Health Organization (WHO) has decided to reclassify gliomas based on molecular markers rather than the traditional anatomical basis; use of Nuclear Medicine techniques e.g. SPECT/PET and Magnetic Resonance Imaging (MRI) techniques based on molecular markers is set to become the future gold standards. This has led to the investigations on potential for the use of non-invasive imaging techniques such as [68Ga]68Ga-RGD positron emission tomography (PET) to be utilised routinely in clinical practice based on angiogenic markers and also the potential to add information that may assist in drug-design and therapeutic decision making. This review aims to provide an overview of the basis of recent advances in glioma imaging using molecular targeting with positron emission tomography and SPECT imaging, as well as the role in patient management i.e. diagnosis, staging, recurrence detection etc.

Keywords

RGD; Integrins; PET; αvβ3; Gliomas; Nuclear Medicine; MRI; Neurosurgery, Angiogenesis; Molecular

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.